Cargando…

Defining the altered glycoproteomic space of the early secretory pathway by class I mannosidase pharmacological inhibition

N-glycosylation is a key process for various biological functions like protein folding, maturation and sorting for the conventional secretory compartment, cell-cell communication and immune response. This is usually accomplished by a complex system of mannosidases in which those from class I have an...

Descripción completa

Detalles Bibliográficos
Autores principales: Munteanu, Cristian V. A., Chirițoiu, Gabriela N., Petrescu, Andrei-Jose, Petrescu, Ștefana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869281/
https://www.ncbi.nlm.nih.gov/pubmed/36699698
http://dx.doi.org/10.3389/fmolb.2022.1064868
_version_ 1784876737559003136
author Munteanu, Cristian V. A.
Chirițoiu, Gabriela N.
Petrescu, Andrei-Jose
Petrescu, Ștefana M.
author_facet Munteanu, Cristian V. A.
Chirițoiu, Gabriela N.
Petrescu, Andrei-Jose
Petrescu, Ștefana M.
author_sort Munteanu, Cristian V. A.
collection PubMed
description N-glycosylation is a key process for various biological functions like protein folding, maturation and sorting for the conventional secretory compartment, cell-cell communication and immune response. This is usually accomplished by a complex system of mannosidases in which those from class I have an outstanding role, commonly involved in the early protein sorting associated to the Endoplasmic Reticulum (ER) in the N-glycan dependent quality control (ERQC) and ER-associated degradation (ERAD). Although these are vital processes in maintaining cellular homeostasis, large-scale analysis studies for this pool of molecules, further denoted as proteins from the early secretory pathway (ESP), were limited addressed. Here, using a custom workflow employing a combination of glycomics and deglycoproteomics analyses, using lectin affinity and selective Endoglycosidase H (Endo H) digestion, we scrutinize the steady-state oligomannosidic glycoprotein load and delineate ESP fraction in melanoma cells. All of these were assessed by applying our workflow for glycosite relative quantification of both the peptide chain and carbohydrate structure in cells with inhibited activity of class I mannosidases after kifunensine treatment. We found that most of the ESP are transient clients involved in cell communication via extracellular matrix, particularly integrin-mediated communication which adopt Man9 N-glycans in kifunensine-treated cells. Moreover, our results reveal that core-fucosylation is decreased subsequent inhibition of class I mannosidases and this could be explained by a general lower protein level of FUT8, the enzyme responsible for fucosylation. By comparing our data with results obtained following downregulation of a key mannosidase in misfolded protein degradation, we mapped both novel and previously suggested endogenous substrate candidates like PCDH2, HLA-B, LAMB2 or members of the integrin family of proteins such as ITGA1 and ITGA4, thus validating the findings obtained using our workflow regarding accumulation and characterization of ESP transitory members following mannosidase class I inhibition. This workflow and the associated dataset not only allowed us to investigate the oligomannosidic glycoprotein fraction but also to delineate differences mediated at glycosite-level upon kifunensine treatment and outline the potential associated cellular responses.
format Online
Article
Text
id pubmed-9869281
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98692812023-01-24 Defining the altered glycoproteomic space of the early secretory pathway by class I mannosidase pharmacological inhibition Munteanu, Cristian V. A. Chirițoiu, Gabriela N. Petrescu, Andrei-Jose Petrescu, Ștefana M. Front Mol Biosci Molecular Biosciences N-glycosylation is a key process for various biological functions like protein folding, maturation and sorting for the conventional secretory compartment, cell-cell communication and immune response. This is usually accomplished by a complex system of mannosidases in which those from class I have an outstanding role, commonly involved in the early protein sorting associated to the Endoplasmic Reticulum (ER) in the N-glycan dependent quality control (ERQC) and ER-associated degradation (ERAD). Although these are vital processes in maintaining cellular homeostasis, large-scale analysis studies for this pool of molecules, further denoted as proteins from the early secretory pathway (ESP), were limited addressed. Here, using a custom workflow employing a combination of glycomics and deglycoproteomics analyses, using lectin affinity and selective Endoglycosidase H (Endo H) digestion, we scrutinize the steady-state oligomannosidic glycoprotein load and delineate ESP fraction in melanoma cells. All of these were assessed by applying our workflow for glycosite relative quantification of both the peptide chain and carbohydrate structure in cells with inhibited activity of class I mannosidases after kifunensine treatment. We found that most of the ESP are transient clients involved in cell communication via extracellular matrix, particularly integrin-mediated communication which adopt Man9 N-glycans in kifunensine-treated cells. Moreover, our results reveal that core-fucosylation is decreased subsequent inhibition of class I mannosidases and this could be explained by a general lower protein level of FUT8, the enzyme responsible for fucosylation. By comparing our data with results obtained following downregulation of a key mannosidase in misfolded protein degradation, we mapped both novel and previously suggested endogenous substrate candidates like PCDH2, HLA-B, LAMB2 or members of the integrin family of proteins such as ITGA1 and ITGA4, thus validating the findings obtained using our workflow regarding accumulation and characterization of ESP transitory members following mannosidase class I inhibition. This workflow and the associated dataset not only allowed us to investigate the oligomannosidic glycoprotein fraction but also to delineate differences mediated at glycosite-level upon kifunensine treatment and outline the potential associated cellular responses. Frontiers Media S.A. 2023-01-09 /pmc/articles/PMC9869281/ /pubmed/36699698 http://dx.doi.org/10.3389/fmolb.2022.1064868 Text en Copyright © 2023 Munteanu, Chirițoiu, Petrescu and Petrescu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Munteanu, Cristian V. A.
Chirițoiu, Gabriela N.
Petrescu, Andrei-Jose
Petrescu, Ștefana M.
Defining the altered glycoproteomic space of the early secretory pathway by class I mannosidase pharmacological inhibition
title Defining the altered glycoproteomic space of the early secretory pathway by class I mannosidase pharmacological inhibition
title_full Defining the altered glycoproteomic space of the early secretory pathway by class I mannosidase pharmacological inhibition
title_fullStr Defining the altered glycoproteomic space of the early secretory pathway by class I mannosidase pharmacological inhibition
title_full_unstemmed Defining the altered glycoproteomic space of the early secretory pathway by class I mannosidase pharmacological inhibition
title_short Defining the altered glycoproteomic space of the early secretory pathway by class I mannosidase pharmacological inhibition
title_sort defining the altered glycoproteomic space of the early secretory pathway by class i mannosidase pharmacological inhibition
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869281/
https://www.ncbi.nlm.nih.gov/pubmed/36699698
http://dx.doi.org/10.3389/fmolb.2022.1064868
work_keys_str_mv AT munteanucristianva definingthealteredglycoproteomicspaceoftheearlysecretorypathwaybyclassimannosidasepharmacologicalinhibition
AT chiritoiugabrielan definingthealteredglycoproteomicspaceoftheearlysecretorypathwaybyclassimannosidasepharmacologicalinhibition
AT petrescuandreijose definingthealteredglycoproteomicspaceoftheearlysecretorypathwaybyclassimannosidasepharmacologicalinhibition
AT petrescustefanam definingthealteredglycoproteomicspaceoftheearlysecretorypathwaybyclassimannosidasepharmacologicalinhibition